The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer

被引:24
作者
Goodson, WH
Moore, DH
Ljung, BM
Chew, K
Florendo, C
Mayall, B
Smith, HS
Waldman, FM
机构
[1] Univ Calif San Francisco, Med Ctr, Dept Surg, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Med Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Med Ctr, Dept Pathol, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Med Ctr, Dept Lab Med, San Francisco, CA 94143 USA
[5] Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA
关键词
breast cancer; bromodeoxyuridine; functional relationship; human study; in vivo; Ki-67; prognosis; proliferation markers;
D O I
10.1023/A:1005926228093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proliferation indices are used, along with other parameters, to estimate the risk of recurrence of breast cancer for individual patients. Because it is unlikely one index will be practical for all patients, it is important to understand the relationship between various indices of proliferation. For this reason, we compared a proliferation index based on in vivo labeling of S-phase tumor cells with the thymidine analog bromodeoxyuridine (BrdUrd), to a proliferation index based on an estimate of the growth fraction with the MIB-1 antibody to the Ki-67 antigen. With informed consent, we gave 145 patients 200 mg/m(2) BrdUrd intravenously just prior to surgical removal of breast cancer. On histology sections, we visually counted S-phase cells which had incorporated BrdUrd using the Br-3 antibody which is specific to DNA-incorporated BrdUrd, and we counted cells in the growth fraction using the MIB-1 antibody to the Ki-67 antigen. We found that both indices were positively correlated with tumor size, number of positive nodes, and tumor grade, and both were negatively correlated with age and estrogen-progesterone receptor positivity. Using a linear functional relationship model, we found that the best (i.e. the maximal) fit between the two indices (correlation coefficient 0.79; p < 0.0001) occurred when each index was square root transformed, as is appropriate when counts follow a Poisson distribution. When we used the median as a cutpoint for each index, the classification of 19 percent of data pairs changed depending upon which index was used. We also estimated that the Ki-67 intercept (1.02 +/- 0.25) was significantly greater than zero. We conclude that the BrdUrd index of DNA synthesis in S-phase correlates highly with the MIB-1 index of the growth fraction, and both indices correlate well with other parameters of tumor aggressiveness. Because this correlation is driven by concordance of the extremes of high and low counts, clinical comparison will be necessary to determine which is the better prognostic marker for human breast cancer.
引用
收藏
页码:155 / 164
页数:10
相关论文
共 26 条
  • [1] HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS
    BLOOM, HJG
    RICHARDSON, WW
    [J]. BRITISH JOURNAL OF CANCER, 1957, 11 (03) : 359 - &
  • [2] MONOCLONAL-ANTIBODY KI-67 - ITS USE IN HISTOPATHOLOGY
    BROWN, DC
    GATTER, KC
    [J]. HISTOPATHOLOGY, 1990, 17 (06) : 489 - 503
  • [3] CHENG CL, 1994, J ROY STAT SOC B MET, V56, P167
  • [4] Efron B., 1994, INTRO BOOTSTRAP, V57, DOI DOI 10.1201/9780429246593
  • [5] CELL-KINETICS OF HUMAN OVARIAN-CANCER WITH IN-VIVO ADMINISTRATION OF BROMODEOXYURIDINE
    ERBA, E
    GIORDANO, M
    DANOVA, M
    MAZZINI, G
    UBEZIO, P
    TORRI, V
    MANGIONI, C
    LANDONI, F
    BOLIS, P
    TENTI, P
    FRANCHI, M
    BABILONTI, L
    RICCARDI, A
    DINCALCI, M
    [J]. ANNALS OF ONCOLOGY, 1994, 5 (07) : 627 - 634
  • [6] INFLUENCES ON MEASUREMENT OF CELLULAR PROLIFERATION BY HISTOLOGY AND FLOW-CYTOMETRY IN MAMMARY CARCINOMAS LABELED IN-VIVO WITH BROMODEOXYURIDINE
    GOING, JJ
    STANTON, PD
    COOKE, TG
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1993, 100 (03) : 218 - 222
  • [7] GOODSON WH, 1993, CANCER, V71, P3914, DOI 10.1002/1097-0142(19930615)71:12<3914::AID-CNCR2820711219>3.0.CO
  • [8] 2-N
  • [9] GOODSON WH, 1991, ARCH SURG-CHICAGO, V126, P1220
  • [10] HOSHINO T, 1979, CANCER, V44, P956, DOI 10.1002/1097-0142(197909)44:3<956::AID-CNCR2820440325>3.0.CO